Key result
Direct oral anticoagulants present unique challenges regarding drug-drug interactions compared to vitamin K antagonists due to fixed-dose regimens and lack of universal laboratory monitoring.
Why the study?
Because direct oral anticoagulants feature fixed-dose regimens and lack universally available laboratory monitoring, managing drug-drug interactions presents a challenge to clinicians.
Highlights the challenges of managing drug-drug interactions with direct oral anticoagulants due to fixed dosing and lack of routine monitoring, emphasizing the need for antithrombotic stewardship.
Requires heightened DOAC interaction vigilance without monitoring; leaves open optimal stewardship tools for polypharmacy.
When clinicians consider selecting an oral anticoagulant medication for their patient, a key advantage of the direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs) is the fewer number of clinically significant drug‐drug interactions. Typically with VKAs, a drug interaction can be managed via monitoring of the international normalized ratio (INR) and subsequent adjustment of the VKA dose. With DOACs having primarily fixed‐dose regimens and laboratory testing that is not universally available or guideline recommended, drug interactions present a challenge to clinicians.
No takes yet. Share an insight, caveat, or question.
Vazquez et al. (2022) conducted a review in Patients requiring oral anticoagulants. Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKAs) was evaluated. Direct oral anticoagulants present unique challenges regarding drug-drug interactions compared to vitamin K antagonists due to fixed-dose regimens and lack of universal laboratory monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: